PhaseBio announces bankruptcy plan confirmation

Published 12/07/2024, 22:08
PhaseBio announces bankruptcy plan confirmation

PhaseBio Pharmaceuticals Inc. has received final approval from the United States Bankruptcy Court for its Chapter 11 bankruptcy plan, according to a recent SEC filing. The plan outlines the liquidation of assets and the winding down of operations through a Liquidation Trust.

The Malvern, Pennsylvania-based company, which focuses on pharmaceutical preparations, had previously filed for bankruptcy on October 23, 2022. On June 26, 2024, the court confirmed the bankruptcy plan, which includes provisions for the distribution of assets to claim holders.

Under the approved plan, holders of priority non-tax claims and secured claims will be paid in full, while general unsecured creditors are anticipated to receive a recovery of approximately 1.6% on their claims. This recovery does not account for any potential additional distributions from the Liquidation Trustee's efforts or the possible sale of the Bentracimab Royalty.

Equity interest holders are not expected to receive any recovery unless general unsecured claims are paid in full, which, based on the company's financial projections, is unlikely. Approximately 50.2 million shares of PhaseBio's common stock will be terminated and cancelled as of the effective date of the plan.

The company's most recent monthly operating report, for the month ending May 31, 2024, listed total assets of approximately $2.7 million and total liabilities of around $41.9 million.

PhaseBio has cautioned investors against placing undue reliance on the monthly operating reports and against speculative trading in the company's securities. The reports, filed for compliance with the Bankruptcy Court, are not prepared in accordance with GAAP and may be subject to future adjustments.

The confirmation of the bankruptcy plan marks a significant step in PhaseBio's Chapter 11 case, as the company moves towards liquidation and cessation of operations. This information is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.